KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Non Operating Income (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Non Operating Income data on record, last reported at -$172000.0 in Q4 2025.

  • For Q4 2025, Non Operating Income fell 101.76% year-over-year to -$172000.0; the TTM value through Dec 2025 reached -$6.6 million, down 164.49%, while the annual FY2025 figure was -$6.6 million, 164.49% down from the prior year.
  • Non Operating Income reached -$172000.0 in Q4 2025 per PCRX's latest filing, down from -$110000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $13.3 million in Q4 2021 and bottomed at -$25.3 million in Q4 2023.
  • Average Non Operating Income over 5 years is -$1.8 million, with a median of -$141500.0 recorded in 2022.
  • The widest YoY moves for Non Operating Income: up 4323.9% in 2025, down 33371.79% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $13.3 million in 2021, then crashed by 99.39% to $81000.0 in 2022, then tumbled by 31301.23% to -$25.3 million in 2023, then soared by 138.74% to $9.8 million in 2024, then crashed by 101.76% to -$172000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were -$172000.0 in Q4 2025, -$110000.0 in Q3 2025, and -$13.1 million in Q2 2025.